
Eduardo de Pablo-FernÃ;ndez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8538095/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurology, 2019, 76, 470.	9.0	205
2	Association between diabetes and subsequent Parkinson disease. Neurology, 2018, 91, e139-e142.	1.1	171
3	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurology, 2017, 74, 970.	9.0	162
4	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. PLoS Medicine, 2017, 14, e1002314.	8.4	152
5	The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 775-789.	2.8	101
6	Neuroendocrine abnormalities in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 176-185.	1.9	70
7	Association between Parkinson's disease and diabetes: Data from NEDICES study. Acta Neurologica Scandinavica, 2017, 136, 732-736.	2.1	48
8	Youngâ€onset multiple system atrophy: Clinical and pathological features. Movement Disorders, 2018, 33, 1099-1107.	3.9	30
9	Colonic transit, high-resolution anorectal manometry and MRI defecography study of constipation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 195-201.	2.2	27
10	Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy. Brain, 2021, 144, 1138-1151.	7.6	24
11	Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 555-561.	1.9	23
12	Hypothalamic α-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease. Movement Disorders, 2017, 32, 296-298.	3.9	22
13	Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 934-936.	1.9	20
14	Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased αâ€synuclein, tau, amyloidâ€Î² or vascular pathology. Neuropathology and Applied Neurobiology, 2021, 47, 1080-1091.	3.2	14
15	The faecal metabolome and mycobiome in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 95, 65-69.	2.2	11
16	Elevated 4Râ€ŧau in astrocytes from asymptomatic carriers of the <i>MAPT</i> 10+16 intronic mutation. Journal of Cellular and Molecular Medicine, 2022, 26, 1327-1331.	3.6	6
17	Dystonia. British Medical Bulletin, 2017, 123, 91-102.	6.9	4
18	Neuropathological progression of clinical Parkinson disease subtypes. Nature Reviews Neurology, 2019, 15, 361-361.	10.1	4

#	Article	IF	CITATIONS
19	Diagnosing Premotor Multiple System Atrophy. Neurology, 2022, 99, .	1.1	4
20	The long-term outcome of impulsive compulsive behaviours in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1288-1289.	1.9	3
21	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. Movement Disorders, 2021, 36, 632-641.	3.9	3
22	Hypothalamic α-synuclein and its relation to autonomic symptoms and neuroendocrine abnormalities in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 223-233.	1.8	2
23	Reply to: Young―onset multiple system atrophy. Movement Disorders, 2018, 33, 1975-1976.	3.9	1
24	OWE-12â€Fungal fumes in faeces – hidden culpritbehindParkinson'sdisease?Afaecal metabolomics stud 2019, , .	y.,	0
25	OWE-1â€Investigation of the metabolome and mycobiome in Parkinson's disease. , 2021, , .		О